Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical...
10 insider purchases on record · latest filing 2025-01-29.
Insiders have also filed 6 sale transactions at OVID.